The estimation of the efficacy of immuno-checkpoint inhibitor in gene mutation for recurrent oral cancer

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K10337
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 57060:Surgical dentistry-related
• Research Institution: Sapporo Medical University
• Principal Investigator: Ogi Kazuhiro 札幌医科大学, 医学部, 講師 (40433114)
• Co-Investigator(Kenkyū-buntansha): 西山 廣陽 札幌医科大学, 医学部, 助教 (60749563) ; 宮本 昇 琉球大学, 医学部附属病院, 助教 (80749565)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: Immunotherapy / squamous cell carcinoma / gene mutation

Outline of Final Research Achievements

The indications of immune checkpoint inhibitors (ICIs) are mainly for recurrent oral cancer. It carefully requires the assessment of the slowly continuous therapeutic effects after administration of ICIs, and the switching from ICIs to cytotoxic anticancer agents or to molecular-targeted agents. In addition, there are no evidence regarding to the administration period. Also, it shows a delayed effect, and prolong a long time until it occurs a tumor immune response. In our research, we were able to verify the relevance of tumor-infiltrating lymphocytes (TIL) and somatic gene mutations in our clinical specimens, resulting from the exploration of some factors for predicting the therapeutic effect of ICI.

Free Research Field

oral cancer

Academic Significance and Societal Importance of the Research Achievements

再発口腔癌に対して, ICI投与前にがん関連遺伝子変異を調べてICIの有効性を検証することができる. これによりirAEなどの有害事象の軽減に繋がり, がん免疫療法を適正な治療法として確立することができる.